{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:41:54Z","timestamp":1772160114531,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF14SA0003"],"award-info":[{"award-number":["NNF14SA0003"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The PLANET trials showed that atorvastatin 80\u2009mg but not rosuvastatin at either 10 or 40\u2009mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL\u2010cholesterol. However, individual changes in both UPCR and LDL\u2010cholesterol during treatment with these statins varied widely between patients. This inter\u2010individual variability could not be explained by patients\u2019 physical or biochemical characteristics. We assessed whether the plasma concentrations of both statins were associated with LDL\u2010cholesterol and UPCR response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The PLANET trials randomized patients with a UPCR of 500\u20105000\u2009mg\/g and fasting LDL\u2010cholesterol &gt;2.33\u2009mmol\/L to a 52\u2010week treatment with atorvastatin 80\u2009mg, rosuvastatin 10 mg or 40\u2009mg. For the current analysis, patients with available samples at week 52 and treatment compliance &gt;80% by pill count were included (N = 295). The main outcome measurements were percentage change in UPCR and absolute change in LDL\u2010cholesterol (delta LDL) from baseline to week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median (interquartile range) plasma concentration at week 52 for atorvastatin 80\u2009mg was 3.9 ng\/mL (IQR: 2.1 to 8.7), for rosuvastatin 10 mg 1.0 ng\/mL (IQR: 0.7 to 2.0) and for rosuvastatin 40\u2009mg 3.5 ng\/mL (IQR: 2.0 to 6.8). Higher plasma concentration of statin was associated with larger LDL\u2010cholesterol reductions at week 52 [rosuvastatin r = \u22120.40 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001); atorvastatin r = \u22120.28 (\n                      <jats:italic>P<\/jats:italic>\n                      = .006)]. The plasma concentration of both statins did not correlate with UPCR change [rosuvastatin r = 0.07 (\n                      <jats:italic>P<\/jats:italic>\n                      = .30); atorvastatin r = 0.16 (\n                      <jats:italic>P<\/jats:italic>\n                      = .13)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individual variation in plasma concentrations of rosuvastatin and atorvastatin was associated with LDL\u2010cholesterol changes in patients. The individual variation in UPCR change was not associated with the plasma concentration of both statins.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13849","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T04:09:36Z","timestamp":1565842176000},"page":"2635-2642","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-1847","authenticated-orcid":false,"given":"Marjolein Y. A. M.","family":"Kroonen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-9008","authenticated-orcid":false,"given":"Jasper","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.31"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39472.580984.AE"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcx040"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-4-201208210-00007"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0545-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.36"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70246-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy159"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342130-00005"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg048"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.24"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1801-z"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90218-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.2000.tb05987.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01454-0"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)80175-6"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.03.008"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13849","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:39:13Z","timestamp":1761863953000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/dom.13849"],"URL":"https:\/\/doi.org\/10.1111\/dom.13849","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13849\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13849\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13849\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13849\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13849\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13849\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"2019-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}